Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harald Sourij

Showing results (1-10 of 258) with videos related to

Pageof 26
Sort By:
Diabetes Research and Clinical Practice|December 1, 2018
Therapeutic options to reduce advanced glycation end products in patients with diabetes mellitus: A reviewPhilipp Jud, Harald Sourij
Current Cardiology Reports|November 19, 2011
Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practiceM Angelyn Bethel, Harald Sourij
International Journal of Pharmaceutics|December 7, 2016
Identification of different shapes, colors and sizes of standard oral dosage forms in diabetes type 2 patients-A pilot studySven Stegemann, Regina Riedl, Harald Sourij
Frontiers in Endocrinology|February 26, 2024
Editorial: Lifestyle intervention approaches in prediabetes or diabetesOthmar Moser, Susanne Kaser, Harald Sourij
Diabetologia|April 8, 2016
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: guidelines, clinical reality and health economic aspectsHermann Toplak, Rudolf Stauber, Harald Sourij
Polish Archives of Internal Medicine|February 26, 2019
A typical clinical presentation of a woman with Köbberling syndromeFelix Aberer, Harald Sourij, Julia K Mader
Diabetes Care|April 29, 2006
Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetesHarald Sourij, Robert Zweiker, Thomas C Wascher
Lancet (London, England)|September 23, 2014
Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' replyRury R Holman, Harald Sourij, Robert M Califf
Frontiers in Endocrinology|December 20, 2023
Low glucose availability potentiates the effects of metformin on model T cell activation and exhaustion markers <i>in vitro</i>Jernej Repas, Lea Peternel, Harald Sourij, et al.
Lancet (London, England)|June 10, 2014
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetesRury R Holman, Harald Sourij, Robert M Califf
Pageof 26

Showing results (1-10 of 258) with videos related to

Sort By:
Pageof 26
Diabetes Research and Clinical Practice|December 1, 2018
Therapeutic options to reduce advanced glycation end products in patients with diabetes mellitus: A reviewPhilipp Jud, Harald Sourij
Current Cardiology Reports|November 19, 2011
Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practiceM Angelyn Bethel, Harald Sourij
International Journal of Pharmaceutics|December 7, 2016
Identification of different shapes, colors and sizes of standard oral dosage forms in diabetes type 2 patients-A pilot studySven Stegemann, Regina Riedl, Harald Sourij
Frontiers in Endocrinology|February 26, 2024
Editorial: Lifestyle intervention approaches in prediabetes or diabetesOthmar Moser, Susanne Kaser, Harald Sourij
Diabetologia|April 8, 2016
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: guidelines, clinical reality and health economic aspectsHermann Toplak, Rudolf Stauber, Harald Sourij
Polish Archives of Internal Medicine|February 26, 2019
A typical clinical presentation of a woman with Köbberling syndromeFelix Aberer, Harald Sourij, Julia K Mader
Diabetes Care|April 29, 2006
Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetesHarald Sourij, Robert Zweiker, Thomas C Wascher
Lancet (London, England)|September 23, 2014
Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes--Authors' replyRury R Holman, Harald Sourij, Robert M Califf
Frontiers in Endocrinology|December 20, 2023
Low glucose availability potentiates the effects of metformin on model T cell activation and exhaustion markers <i>in vitro</i>Jernej Repas, Lea Peternel, Harald Sourij, et al.
Lancet (London, England)|June 10, 2014
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetesRury R Holman, Harald Sourij, Robert M Califf
Pageof 26